Cancer drug specialist Exelixis (EXEL 5.02%) was quite the stock market star on Friday. Following news that it's making a big, shareholder-pleasing move, market players piled into the company to push its shares 5% higher on the day. This provided some light in what was generally a gloomy trading session, with the S&P 500 index falling by 1.7%.
After market close on Thursday, Exelixis announced that it will launch a new share repurchase program, authorized for up to $500 million worth of its common stock before this coming Dec. 31. This will kick in once the current buyback program, also capped at $500 million, is exhausted. The company anticipates that will occur in this year's second calendar quarter.
As with most repurchase programs, this one will take place from time to time and involve various amounts.
The new initiative will be Exelixis's fourth; the previous one was launched in August 2024. The pharmaceutical company is hardly a slacker when it comes to snapping up its own stock; the company revealed that it expended more than $1.2 billion on the activity through the end of 2024.
Investors tend to welcome news of stock repurchases because they mean that a company is helping prop up the value of its equity by dipping into the market for it now and again. While a buyback program should never be the leading reason for buying any stock, it is an encouraging sign that a management team has that sort of commitment.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。